文献速递生殖医学

自然周期中补充黄体酮可提高冻融胚胎移植后的活产率——一项随机对照试验

Progesterone supplementation in natural cycles improves live birth rates after embryo transfer of frozen-thawed embryos-a randomized controlled trial.
PubMed 文献 · Hum Reprod · 2022-01-01

这项前瞻性随机对照试验在两家大学诊所纳入500名自然周期行冻融胚胎移植的女性,1:1分为阴道黄体酮片组(100mg每日两次,自移植日起)与对照组。黄体酮组活产率34.2% vs 对照组24.1%(OR 1.635,95%CI 1.102-2.428,P=0.017),妊娠率与临床妊娠率亦升高,生化妊娠率与流产率无显著差异,血清黄体酮浓度与结局无相关性。

要点

  • 自然周期冻融胚胎移植后补充阴道黄体酮片100mg每日两次可提高活产率。
  • 黄体酮组活产率34.2% vs 对照组24.1%(OR 1.635,95%CI 1.102-2.428,P=0.017)。
  • 生化妊娠率与流产率两组无显著差异,血清黄体酮浓度与结局无相关性。

核心结论

  • 自然周期中补充黄体酮提高了冻融胚胎移植后的活产数,作者认为应考虑将其引入临床常规。

研究设计与样本

  • 前瞻性随机对照试验,在两家大学诊所进行,2013年2月至2018年3月共随机500名受试者,1:1分配。
  • 672名月经规律女性受邀,500名同意参与,最终488名纳入分析。
  • 随机化在自然周期冻融胚胎移植后使用不透明密封信封进行。
  • 胚胎在Day 2、3、5或6冷冻。
  • 主要结局为活产率;次要结局为妊娠率、生化妊娠率、临床妊娠率、流产率及移植日血清黄体酮浓度与活产率的可能关联。

主要发现

  • 黄体酮补充组243例中83例(34.2%)活产,对照组245例中59例(24.1%)活产(OR 1.635,95%CI 1.102-2.428,P=0.017)。
  • 妊娠数分别为243例中104例(42.8%)与245例中83例(33.9%)(OR 1.465,95%CI 1.012-2.108,P=0.049)。
  • 临床妊娠数分别为243例中91例(37.4%)与245例中70例(28.6%)(OR 1.497,95%CI 1.024-2.188,P=0.043)。
  • 生化妊娠率与流产率无显著差异。
  • 结局与血清黄体酮浓度无相关性。

关键数值与推荐

  • 黄体酮补充组:阴道黄体酮片100mg每日两次,自胚胎移植日开始。
  • 对照组:不给任何治疗。

临床怎么用

  • 作者认为自然周期中补充黄体酮提高了冻融胚胎移植后的活产数,应考虑将其引入临床常规。

局限性

  • 研究未设盲,因为无法获得安慰剂片。
  • 补充自胚胎移植日开始,不论胚胎日龄,导致Day 5/6胚胎的补充时间短于Day 2/3胚胎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does supplementation with vaginal tablets of progesterone after frozen-thawed embryo transfer in natural cycles improve the live birth rate? SUMMARY ANSWER: Supplementation with vaginal tablets of progesterone after frozen-thawed embryo transfer in natural cycles significantly improves the number of live births. WHAT IS KNOWN ALREADY: Progesterone supplementation during luteal phase and early pregnancy may improve the number of live births after frozen-thawed embryo transfer. However, due to the limited number of previous studies, being mainly retrospective, evidence is still limited. STUDY DESIGN, SIZE, DURATION: This is a prospective randomized controlled trial, performed at two university clinics. In total, 500 subjects were randomized with a 1:1 allocation into two groups, during the period February 2013 to March 2018. Randomization was performed after a frozen embryo transfer in a natural cycle by use of opaque sealed envelopes. The primary outcome was live birth rate; secondary outcomes were pregnancy, biochemical pregnancy, clinical pregnancy and miscarriage rate, and if there was a possible association between the serum progesterone concentration on the day of embryo transfer and live birth rate. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women, receiving embryo transfer in natural cycles participated in the study. The embryos were frozen on Day 2, 3, 5 or 6. In total, 672 women having regular menstrual cycles were invited to participate in the study; of those, 500 agreed to participate and 488 were finally included in the study. Half of the study subjects received progesterone supplementation with progesterone vaginal tablets, 100 mg twice daily, starting from the day of embryo transfer. The other half of the subjects were not given any treatment. Blood samples for serum progesterone measurements were collected from all subjects on the day of embryo transfer. MAIN RESULTS AND THE ROLE OF CHANCE: There were no differences in background characteristics between the study groups. In the progesterone supplemented group, 83 of 243 patients (34.2%) had a live birth, compared to 59 of 245 patients (24.1%) in the control group (odds ratio 1.635, 95% CI 1.102-2.428, P = 0.017*). The number of pregnancies was 104 of 243 (42.8%) and 83 of 245 (33.9%), respectively (odds ratio 1.465, 95% CI 1.012-2.108, P = 0.049*) and the number of clinical pregnancies was 91 of 243 (37.4%) and 70 of 245 (28.6%), respectively (odds ratio 1.497, 95% CI 1.024-2.188, P = 0.043*). There were no significant differences in biochemical pregnancy rate or miscarriage rate. There was no correlation between outcome and serum progesterone concentration. LIMITATIONS, REASONS FOR CAUTION: The study was not blinded because placebo tablets were not available. Supplementation started on embryo transfer day, regardless of the age of the embryos, which resulted in a shorter supplementation time for Day 5/6 embryos compared to Day 2/3 embryos. WIDER IMPLICATIONS OF THE FINDINGS: Supplementation with progesterone in natural cycles improved the number of live births after frozen-thawed embryo transfer and should therefore be considered for introduction in clinical routine. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by Uppsala University, the Uppsala-Family Planning Foundation, and Ferring Pharmaceuticals AB, Malmö, Sweden. The authors have no personal conflicting interests to declare. TRIAL REGISTRATION NUMBER: NL4152. TRIAL REGISTRATION DATE: 5 December 2013. DATE OF FIRST PATIENT’S ENROLMENT: 18 February 2013.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Wånggren K, Dahlgren Granbom M, Iliadis SI, et al. Progesterone supplementation in natural cycles improves live birth rates after embryo transfer of frozen-thawed embryos-a randomized controlled trial. Hum Reprod. 2022. PMID: 35972453. doi:10.1093/humrep/deac181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。